Potential greater than additive vasorelaxant actions of milrinone and nitroglycerin on human conduit arteries
- 1 February 1996
- journal article
- Published by Wiley in British Journal of Clinical Pharmacology
- Vol. 41 (2) , 101-107
- https://doi.org/10.1111/j.1365-2125.1996.tb00166.x
Abstract
1 The mechanism of vasorelaxation for phosphodiesterase III inhibitors is mediated by increase of cAMP whereas for nitrovasodilators, cGMP. The purpose of this study was to test the hypothesis that the phosphodiesterase I inhibitor milrinone and nitroglycerin (NTG) may have greater than additive effects in human arteries.2 Internal mammary artery segments (IMA,n= 90) taken from 23 patients were studied in organ chambers. The effect of milrinone (3 μM), NTG (10 nM), or the combination was tested in IMA rings precontracted with potassium (K+, 25 mM) or U46619 (10 nM). Concentration‐contraction curves for K+or U46619 were established in other rings treated with milrinone (70 μM), NTG (0.1 μM), or the combination for 10 min.3 In K+‐induced contraction, the combination produced more relaxation (45.4%) than did either milrinone (7.9%, P < 0.05) or NTG (3.8%, P < 0.05) alone. This relaxation was significantly more than the theoretical overadditive effect (P < 0.05). Similar results were seen in U46619‐induced contraction (94.1% by the combinationvs70.7% by milrinone, P < 0.05, or 36.1% by NTG, P < 0.05). Pretreatment with the combination depressed contraction to a higher extend compared with milrinone alone (P < 0.05) for the K+‐induced contraction and to NTG alone (P < 0.05) in U46619‐induced contraction. Treatment with the combination also shifted EC50rightward and this shift was significantly more than that caused by treatment with NTG alone (P < O.O5).4 We conclude that there is a greater than additive vasorelaxant effect of PDE III inhibitors and nitrovasodilators in human conduit arteries. This effect may be beneficial to patients undergoing coronary artery bypass grafting and to other patients requiring these vasodilators. Reduced doses of the vasodilators in concentration may be sufficient to produce vasodilatation similar to that produced by either of them alone at higher concentrations.Keywords
This publication has 36 references indexed in Scilit:
- Species-Dependent Pharmacodynamic Effects of the Selective Low Km Cyclic AMP Phosphodiesterase III Inhibitors WIN 58993 and WIN 62005Journal of Cardiovascular Pharmacology, 1995
- Inhibitory effects of calcium antagonists on alpha‐adrenoceptor‐ mediated contraction in the human internal mammary artery.British Journal of Clinical Pharmacology, 1994
- Hypoperfusion after arterial bypass graftingThe Annals of Thoracic Surgery, 1993
- Synergistic actions of nitrovasodilators and isoprenaline on rat aortic smooth muscleEuropean Journal of Pharmacology, 1991
- Primary sequence of cyclic nucleotide phosphodiesterase isozymes and the design of selective inhibitorsTrends in Pharmacological Sciences, 1990
- Biochemical aspects of inhibition of cardiovascular low (Km) cyclic adenosine monophosphate phosphodiesteraseThe American Journal of Cardiology, 1989
- Reactivity of the Canine Isolated Internal Mammary Artery, Saphenous Vein, and Coronary Artery to Constrictor and Dilator SubstancesJournal of Cardiovascular Pharmacology, 1988
- Early Postoperative Spasm in Left Internal Mammary Artery Bypass GraftsThe Annals of Thoracic Surgery, 1987
- The Pharmacological and Physiological Role of Cyclic GMP in Vascular Smooth Muscle RelaxationAnnual Review of Pharmacology and Toxicology, 1985
- Cyclic Nucleotides and Regulation of Vascular Smooth MuscleJournal of Cardiovascular Pharmacology, 1984